Qube Research & Technologies LTD Adc Therapeutics Sa Transaction History

Qube Research & Technologies LTD

  • $65.7 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023
SELL
$0.72 - $2.37 $50,161 - $165,115
-69,669 Reduced 99.7%
207 $0
Q2 2023

Aug 14, 2023
SELL
$1.9 - $2.66 $13,851 - $19,391
-7,290 Reduced 9.45%
69,876 $150,000
Q1 2023

May 15, 2023
BUY
$1.92 - $5.45 $148,158 - $420,554
77,166 New
77,166 $150,000

Others Institutions Holding ADCT

# of Institutions
80
Shares Held
55.1M
Call Options Held
82.7K
Put Options Held
31.5K
View Full List

About ADC Therapeutics SA

ADCT Quotes by TradingView
  • Ticker ADCT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,645,296
  • Market Cap $270M
  • Description
  • ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...
More about ADCT
Track This Portfolio

Track Qube Research & Technologies LTD Portfolio

Follow Qube Research & Technologies LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email